HRP20000031A2 - O-substituted hydroxycumaranone derivatives as antitumor and antimetastatic agents - Google Patents
O-substituted hydroxycumaranone derivatives as antitumor and antimetastatic agents Download PDFInfo
- Publication number
- HRP20000031A2 HRP20000031A2 HR20000031A HRP20000031A HRP20000031A2 HR P20000031 A2 HRP20000031 A2 HR P20000031A2 HR 20000031 A HR20000031 A HR 20000031A HR P20000031 A HRP20000031 A HR P20000031A HR P20000031 A2 HRP20000031 A2 HR P20000031A2
- Authority
- HR
- Croatia
- Prior art keywords
- group
- alkyl
- compound according
- integer
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/83—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Furan Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP97113190 | 1997-07-31 | ||
| EP98106946 | 1998-04-16 | ||
| PCT/EP1998/004619 WO1999006387A2 (en) | 1997-07-31 | 1998-07-23 | O-substituted hydroxycumaranone derivatives as antitumor and antimetastatic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20000031A2 true HRP20000031A2 (en) | 2000-10-31 |
Family
ID=26145681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20000031A HRP20000031A2 (en) | 1997-07-31 | 1998-07-23 | O-substituted hydroxycumaranone derivatives as antitumor and antimetastatic agents |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US6200989B1 (pt) |
| EP (1) | EP1012147B1 (pt) |
| JP (1) | JP3241711B2 (pt) |
| KR (1) | KR100343067B1 (pt) |
| AR (1) | AR013374A1 (pt) |
| AT (1) | ATE308535T1 (pt) |
| AU (1) | AU745839B2 (pt) |
| BR (1) | BR9811589A (pt) |
| CA (1) | CA2296476A1 (pt) |
| DE (1) | DE69832184D1 (pt) |
| HR (1) | HRP20000031A2 (pt) |
| HU (1) | HUP0004221A2 (pt) |
| ID (1) | ID24525A (pt) |
| IL (1) | IL134193A0 (pt) |
| MA (1) | MA26528A1 (pt) |
| NO (1) | NO20000366L (pt) |
| PE (1) | PE106099A1 (pt) |
| PL (1) | PL338614A1 (pt) |
| TR (1) | TR200000272T2 (pt) |
| UY (1) | UY25114A1 (pt) |
| WO (1) | WO1999006387A2 (pt) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU736869B2 (en) * | 1999-01-30 | 2001-08-02 | Roche Diagnostics Gmbh | O-substituted hydroxycoumaranone derivatives as antitumor and antimetastatic agents |
| US7514406B2 (en) * | 2001-11-27 | 2009-04-07 | Fred Hutchinson Cancer Research Center | Methods for inhibiting deacetylase activity |
| AU2002358158A1 (en) * | 2001-12-19 | 2003-06-30 | D. Collen Research Foundation | Use of urokinase receptor antagonists to modulate ischemiareperfusion injury |
| WO2004076444A2 (en) * | 2003-02-25 | 2004-09-10 | F. Hoffmann-La Roche Ag | Novel hydroxycoumaranone derivatives as antitumor and antimetastatic |
| MX2009004558A (es) * | 2006-10-27 | 2009-06-10 | Univ Tokyo | Compuesto amida o su sal, e inhibidor de formacion de biopelicula, quitador de biopelicula y bactericida usando cada uno el compuesto amida o su sal. |
| US8258307B2 (en) | 2006-11-07 | 2012-09-04 | University Of Tokyo | Amide compound or salt thereof, and biofilm inhibitor, biofilm remover and disinfectant containing the same |
| GB2462022B (en) | 2008-06-16 | 2011-05-25 | Biovascular Inc | Controlled release compositions of agents that reduce circulating levels of platelets and methods thereof |
| PT109740B (pt) * | 2016-11-14 | 2020-07-30 | Hovione Farmaciencia Sa | Processo para a preparação de brometo de umeclidínio |
| EP4092013A1 (en) | 2017-06-20 | 2022-11-23 | Imbria Pharmaceuticals, Inc. | Compositions and methods for increasing efficiency of cardiac metabolism |
| RU2764243C2 (ru) | 2017-09-22 | 2022-01-14 | ДЖУБИЛАНТ ЭПИПЭД ЭлЭлСи | Гетероциклические соединения в качестве ингибиторов PAD |
| CA3076476A1 (en) | 2017-10-18 | 2019-04-25 | Jubilant Epipad LLC | Imidazo-pyridine compounds as pad inhibitors |
| WO2019087214A1 (en) | 2017-11-06 | 2019-05-09 | Jubilant Biosys Limited | Pyrimidine derivatives as inhibitors of pd1/pd-l1 activation |
| PL3704120T3 (pl) | 2017-11-24 | 2024-09-16 | Jubilant Episcribe Llc | Związki heterocykliczne jako inhibitory prmt5 |
| MX2020006115A (es) * | 2017-12-13 | 2020-11-09 | Praxis Biotech LLC | Inhibidores de la vía de respuesta al estrés integrada. |
| BR112020018610A2 (pt) | 2018-03-13 | 2020-12-29 | Jubilant Prodel LLC | Compostos de fórmula i, fórmula ii, fórmula iii, fórmula iv, fórmula v, fórmula vi, ou seus polimorfos, estereoisômeros, tautômeros, profármacos, solvatos e sais farmaceuticamente aceitáveis dos mesmos e uso dos mesmos; processo de preparação; composição farmacêutica; e método para o tratamento e/ou prevenção de várias doenças, que incluem câncer e doenças infecciosas |
| MX2020013269A (es) * | 2018-06-05 | 2021-02-18 | Praxis Biotech LLC | Inhibidores de la vía de respuesta al estrés integrada. |
| EP4497474A3 (en) | 2018-10-17 | 2025-04-23 | Imbria Pharmaceuticals, Inc. | Methods of treating rheumatic diseases using trimetazidine-based compounds |
| JP6611029B1 (ja) * | 2018-11-05 | 2019-11-27 | プキョン ナショナル ユニバーシティ インダストリ ユニバーシティ コーポレーション ファウンデーションＰｕｋｙｏｎｇ Ｎａｔｉｏｎａｌ Ｕｎｉｖｅｒｓｉｔｙ Ｉｎｄｕｓｔｒｙ−Ｕｎｉｖｅｒｓｉｔｙ Ｃｏｏｐｅｒａｔｉｏｎ Ｆｏｕｎｄａｔｉｏｎ | 高周波超音波多焦点変換器、その製造装置、および製造方法 |
| CN114466654A (zh) | 2019-06-12 | 2022-05-10 | 普拉西斯生物技术有限责任公司 | 整合应激反应通路调节剂 |
| US11780811B2 (en) | 2020-06-30 | 2023-10-10 | Imbria Pharmaceuticals, Inc. | Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate |
| US11530184B2 (en) | 2020-06-30 | 2022-12-20 | Imbria Pharmaceuticals, Inc. | Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate |
| US11883396B2 (en) | 2021-05-03 | 2024-01-30 | Imbria Pharmaceuticals, Inc. | Methods of treating kidney conditions using modified forms of trimetazidine |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2901336A1 (de) | 1979-01-15 | 1980-07-24 | Boehringer Mannheim Gmbh | Neue arylether, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel |
| DE3209271A1 (de) | 1982-03-13 | 1983-09-15 | Boehringer Mannheim Gmbh, 6800 Mannheim | Bicyclische phenolether, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel |
| EP0192671B1 (en) * | 1984-08-13 | 1993-12-29 | Biotechnology Australia Pty. Ltd. | Minactivin |
| US5747458A (en) * | 1995-06-07 | 1998-05-05 | Chiron Corporation | Urokinase receptor ligands |
-
1998
- 1998-07-23 HR HR20000031A patent/HRP20000031A2/hr not_active Application Discontinuation
- 1998-07-23 IL IL13419398A patent/IL134193A0/xx unknown
- 1998-07-23 WO PCT/EP1998/004619 patent/WO1999006387A2/en not_active Ceased
- 1998-07-23 AU AU91559/98A patent/AU745839B2/en not_active Ceased
- 1998-07-23 TR TR2000/00272T patent/TR200000272T2/xx unknown
- 1998-07-23 BR BR9811589-8A patent/BR9811589A/pt not_active Application Discontinuation
- 1998-07-23 PL PL98338614A patent/PL338614A1/xx not_active Application Discontinuation
- 1998-07-23 HU HU0004221A patent/HUP0004221A2/hu unknown
- 1998-07-23 ID IDW20000173A patent/ID24525A/id unknown
- 1998-07-23 KR KR1020007000941A patent/KR100343067B1/ko not_active Expired - Fee Related
- 1998-07-23 AT AT98943771T patent/ATE308535T1/de not_active IP Right Cessation
- 1998-07-23 EP EP98943771A patent/EP1012147B1/en not_active Expired - Lifetime
- 1998-07-23 CA CA002296476A patent/CA2296476A1/en not_active Abandoned
- 1998-07-23 DE DE69832184T patent/DE69832184D1/de not_active Expired - Lifetime
- 1998-07-23 JP JP2000505146A patent/JP3241711B2/ja not_active Expired - Fee Related
- 1998-07-29 AR ARP980103732A patent/AR013374A1/es unknown
- 1998-07-29 UY UY25114A patent/UY25114A1/es not_active Application Discontinuation
- 1998-07-30 PE PE1998000679A patent/PE106099A1/es not_active Application Discontinuation
- 1998-07-31 MA MA25200A patent/MA26528A1/fr unknown
-
1999
- 1999-09-22 US US09/401,403 patent/US6200989B1/en not_active Expired - Fee Related
-
2000
- 2000-01-25 NO NO20000366A patent/NO20000366L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20000366D0 (no) | 2000-01-25 |
| IL134193A0 (en) | 2001-04-30 |
| HUP0004221A2 (hu) | 2001-04-28 |
| PE106099A1 (es) | 1999-11-11 |
| EP1012147A2 (en) | 2000-06-28 |
| CA2296476A1 (en) | 1999-02-11 |
| WO1999006387A3 (en) | 1999-04-22 |
| KR100343067B1 (ko) | 2002-07-03 |
| NO20000366L (no) | 2000-01-25 |
| JP2001512113A (ja) | 2001-08-21 |
| ATE308535T1 (de) | 2005-11-15 |
| AU745839B2 (en) | 2002-04-11 |
| EP1012147B1 (en) | 2005-11-02 |
| AR013374A1 (es) | 2000-12-27 |
| TR200000272T2 (tr) | 2000-09-21 |
| AU9155998A (en) | 1999-02-22 |
| WO1999006387A2 (en) | 1999-02-11 |
| UY25114A1 (es) | 2001-01-31 |
| BR9811589A (pt) | 2000-09-19 |
| KR20010022362A (ko) | 2001-03-15 |
| DE69832184D1 (de) | 2005-12-08 |
| ID24525A (id) | 2000-07-20 |
| MA26528A1 (fr) | 2004-12-20 |
| JP3241711B2 (ja) | 2001-12-25 |
| US6200989B1 (en) | 2001-03-13 |
| PL338614A1 (en) | 2000-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20000031A2 (en) | O-substituted hydroxycumaranone derivatives as antitumor and antimetastatic agents | |
| US9403823B2 (en) | Protein kinase inhibitors | |
| CA2031463C (en) | Heterocyclic substituted acylaminothiazoles, their preparation and pharmaceutical compositions containing them | |
| CS235023B2 (en) | Method of thromboxan-synthetase's naphtalene and benzocyclic inhibitors' production | |
| US7078429B2 (en) | Substituted 3-carbonyl-1H-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | |
| US7375131B2 (en) | NF-κB inhibitors | |
| PL212119B1 (pl) | Acylowane, heteroarylo-skondensowane cykloalkenyloaminy, zastosowanie ich jako środków leczniczych, zastosowanie ich do wytwarzania środka leczniczego oraz preparat farmaceutyczny | |
| JPH072840A (ja) | ロイコトリエン生合成の阻害物質としての（アザアリールメトキシ）インドール | |
| JP2002542235A (ja) | ＦａｂＩ阻害剤 | |
| JP2004523475A (ja) | タンパク質Ｊｕｎキナーゼのインヒビターとしての医薬的活性ベンズスルホンアミド誘導体 | |
| US6518267B1 (en) | Protease inhibitors | |
| JPH0987282A (ja) | チアゾール誘導体 | |
| JP2003510320A (ja) | 薬剤活性のあるスルホニルアミノ酸誘導体 | |
| WO1999062555A1 (en) | Remedies for itching containing pgd2 antagonists | |
| CS226021B2 (en) | Method of presparing piperidine propylderivatives | |
| CZ2000343A3 (cs) | O-Substituované hydroxykumaronové deriváty jako protinádorová a protimetastázová činidla | |
| KR100387275B1 (ko) | 항종양 및 항전이 약제로서의 ｏ-치환된 히드록시쿠마라논유도체 | |
| CN1129591C (zh) | 作为抗肿瘤和抗转移试剂的邻位取代的羟基苯并呋喃－3－酮衍生物 | |
| JP2003277263A (ja) | 医薬組成物 | |
| MXPA00000702A (en) | O-substituted hydroxycumaranone derivatives as antitumor and antimetastatic agents | |
| MXPA00000960A (en) | 2-alkylidene hydroxycoumaranone derivatives | |
| EP1026165A1 (en) | O-substituted Hydroxycoumaranone derivatives as antitumor and antimetastatic agents | |
| HK1029791A (en) | O-substituted hydroxycumaranone derivatives as antitumor and antimetastatic agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
| OBST | Application withdrawn |